Repligen (NASDAQ:RGEN – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday.
Other equities research analysts also recently issued reports about the stock. Wells Fargo & Company lowered their price target on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. Stephens upgraded shares of Repligen to an “overweight” rating and set a $160.00 price target for the company in a report on Tuesday, July 22nd. HC Wainwright reiterated a “buy” rating and set a $180.00 price target on shares of Repligen in a report on Wednesday, September 3rd. Barclays lifted their price target on shares of Repligen from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Finally, Evercore ISI lifted their price target on shares of Repligen from $155.00 to $175.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $169.62.
View Our Latest Stock Report on Repligen
Repligen Stock Performance
Repligen (NASDAQ:RGEN – Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analysts’ expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts expect that Repligen will post 1.72 earnings per share for the current fiscal year.
Insider Transactions at Repligen
In related news, Director Martin D. Madaus bought 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.
Institutional Investors Weigh In On Repligen
A number of institutional investors have recently bought and sold shares of the stock. Twin Tree Management LP acquired a new position in Repligen during the first quarter valued at approximately $29,000. Hantz Financial Services Inc. lifted its position in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares in the last quarter. Signaturefd LLC lifted its position in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 128 shares in the last quarter. CWM LLC lifted its position in Repligen by 67.2% during the third quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. lifted its position in Repligen by 110.3% during the first quarter. Center for Financial Planning Inc. now owns 368 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 193 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Featured Stories
- Five stocks we like better than Repligen
- Investing in Construction Stocks
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- How to Read Stock Charts for Beginners
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.